Company news

Anavex Life Sciences Corp. news in 2025

Anavex Life Sciences Corp.'s news releases, calls and decks from 2025, newest first.

View company

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

December 17, 2025

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

December 11, 2025

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 25, 2025

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

November 24, 2025

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

November 18, 2025

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

November 17, 2025

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease

November 13, 2025

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

October 28, 2025

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

October 9, 2025

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

October 1, 2025

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

October 1, 2025

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

September 29, 2025

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

September 8, 2025

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

September 1, 2025

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

August 25, 2025

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease

August 19, 2025

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

August 11, 2025

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

August 4, 2025

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

July 30, 2025

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 12, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 5, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

April 30, 2025

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

April 29, 2025

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

April 22, 2025

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

April 20, 2025

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

April 4, 2025

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

March 30, 2025

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

February 23, 2025

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

February 11, 2025

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

February 4, 2025

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

January 26, 2025

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

January 14, 2025

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

January 12, 2025

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025